REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot146710.32687/1561-5936-2022-26-4-286-291Original ArticleNew clinical developments in drug therapy for ovarian cancer: results of the annual congress «Cancer in women» 2022AndreevD. A.andreevda@zdrav.mos.ruZavyalovA. A.-Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentState Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency1512202226428629106122022Copyright © 2022,2022Introduction. In the Russian Federation, a trend towards an increase in diseases of the female reproductive system is recorded (38% is the proportion of patients with this pathology who have been under dispensary observation for at least 5 years). Over the years, new results from randomized, controlled clinical trials in women with cancer have been accumulating. A serious challenge for scientists is the problem of overcoming the phenomenon of «escape» of the tumor during systemic drug therapy. In this regard, the rationale for choosing the most effective treatment options is being carried out, by determining predictive and prognostic biomarkers. From March 18 to 21, 2022, the Women's Cancer Annual Congress (USA), organized by the Gynecological Oncology Society, was held, where, among others, important results of clinical trials of ovarian cancer therapy were announced.Target. Summarizing the results of clinical trials discussed on the digital platform of the Dutch educational platform for healthcare professionals in connection with their presentation at the Congress of the Oncogynecological Society on Cancer of the Female Reproductive System in March 2022.Materials and methods. The scientific study was based on the results of a search in the database of the Dutch educational platform for healthcare professionals, the PubMed / Medline database and the Google search engine. We analyzed the results published at the beginning of 2022.Results. Systematized and studied the results of new clinical developments on the drug therapy of patients with ovarian cancer, presented at the congress of the Oncogynecological Society. To date, breakthrough results of innovative clinical studies have been obtained in the world with the definition of effective approaches to the choice of individualized targeted, immuno- and chemotherapy for the treatment of patients with ovarian cancer: SOLO3, PRIME, SORAYA, iPOCC, ARTISTRY-1, etc.Discussion and conclusions. Taking into account the results of the conference, it seems clear that personalized technologies are a long-awaited and promising approach. Despite many challenges, these individualized treatment principles are slowly becoming the daily reality of oncological care for ovarian cancer patients.ovarian cancerclinical trialstargeted therapybiomarkersрак яичниковклинические исследованиятаргетная терапиябиомаркеры1.Ailia M. J., Thakur N., Chong Y., Yim K. Tumor budding in gynecologic cancer as a marker for poor survival: a systematic review and meta-analysis of the perspectives of epithelial-mesenchymal transition // Cancers (Basel). 2022. Vol. 14, N 6. P. 1431. DOI: 10.3390/cancers140614312.Солопова А. Г., Власина А. Ю., Идрисова Л. Э. и др. Реабилитация онкогинекологических больных: актуальные проблемы и возможные решения // Вестник восстановительной медицины. 2019. № 5. С. 87-96.3.Ko E. M., Bekelman J. E., Hicks-Courant K. et al. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers // Gynecol. Oncol. 2022. Vol. 164, N 2. P. 295-303. DOI: 10.1016/j.ygyno.2021.12.0014.Bairi K. El, Amrani M. The power of biomarkers in transforming patients care in gynecologic oncology // Curr. Drug Targets. 2020. Vol. 21, N 10. P. 944-945. DOI: 10.2174/1389450121102006241049425.Hanker L. C., Loibl S., Burchardi N. et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy // Ann. Oncol. 2012. Vol. 23, N 10. P. 2605-2612. DOI: 10.1093/annonc/mds2036.Moore K. N., Oza A. M., Colombo N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I // Ann. Oncol. 2021. Vol. 32, N 6. P. 757-765. DOI: 10.1016/j.annonc.2021.02.0177.Walker J. L., Brady M. F., Wenzel L. et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study //j. Clin. Oncol. 2019. Vol. 37, N 16. P. 1380-1390. DOI: 10.1200/JCO.18.015688.Boni V., Winer I. S., Gilbert L. et al. ARTISTRY-1: nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors //j. Clin. Oncol. 2021. Vol. 39, N 15, Suppl. P. 2513. DOI: 10.1200/JCO.2021.39.15\\_suppl.25139.Bodurtha Smith A. J., Pena D., Ko E. Insurance-mediated disparities in gynecologic oncology care // Obstet. Gynecol. 2022. Vol. 139, N 2. P. 305-312. DOI: 10.1097/AOG.000000000000464310.van Riet J., Saha C., Strepis N. et al. CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue // Commun. Biol. 2022. Vol. 5, N 1. P. 338. DOI: 10.1038/s42003-022-03249-411.López-Guerrero J. A., Mendiola M., Pérez-Fidalgo J. A. et al. Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network // Cancers (Basel). 2022. Vol. 14, N 8. P. 1965. DOI: 10.3390/cancers14081965